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 I heard about this internship at Mt. Sinai Medical Center in Manhatten, NY from my 
cousin who is a program director in the Department of Oncological Sciences.  Even though this 
program was geared toward students interested in attending medical school, I saw value in the 
research experience this internship could provide me with. 
 I was placed in the Oncological Sciences department, located on the 13th floor of the 
Icahn Building. My mentor was Dr. Miriam Merad, MD, PhD, although most of my work was on 
a project in Dr. Woo’s lab. The reason for this is due to the amount of animal work involved in 
the project for Dr. Woo’s lab. Being that I am interested in veterinary medicine, the researchers 
were willing to let me help on their experiments that involve any sort of animal work, so I 
floated among the technicians and different labs on the floor. This allowed me to gain experience 
with many different animal procedures, including parabiotics with mice, gavage, hepatic artery 
injections, suturing, portal vein injections, and other animal protocols. All of these experiences 
are applicable to a career in veterinary medicine and have really opened my eyes to what I can do 
with an Animal Science degree or Doctorate of Veterinary Medicine besides being a general 
practitioner. The project that I was involved in the most is looking at using an oncolytic virus, 
specifically vesicular stomatitis virus (VSV), as a treatment option for patients with 
hepatocellular carcinoma (HCC). 
 On a daily basis, I gathered and recorded body weights on a triple beam balance and 
recorded observations on the general health and appearance of the rats, looking for signs of 
neurotoxicity. Since this treatment is going to the FDA, everything from the health of the rats to 
the lot number on the isoflourane must be recorded on standard sheets.   I calculated the dosage 
of IFN alpha depending on the weight of the animal, set-up the procedural area, drew up the 
correct amount in the syringe, and helped restrain the animals. What I learned while doing this 
procedure several times is that the warmer the water is for the tails to soak, the more apparent the 
vein and artery became and the easier the IV injections were.  For the procedure with the second 
group of ten rats, I was taught and eventually allowed to prepare the surgical site by shaving and 
sterilizing the abdominal area. I opened the rats via a midline laparotomy (~3 cm long) and 
prepared the area for the procedure. After the virus was injected into the hepatic artery, I sutured 
the rats closed and gave a subcutaneous analgesic injection and ear tagged each rat with their 
appropriate identifying number in case the tail identification wore off. 
 Unfortunately, I was not able to see the project to completion as the results from 
pathology take several months to come back to the researchers.  From the research I conducted 
and talking to the researchers conducting the study, the results from this current study should be 
more effective than the previous study that was conducted where interferon alpha was not added.  
The following paper presents the material to the reader and the data tables were taken from the 
previous study conducted by the same group of researchers.  It can be assumed the results would 
be better than the presented data.    
 ABSTRACT 
 
Hepatocellular carcinoma (HCC) is a type of liver cancer common in adults that accounts for 
over one million cases annually (Altomonte et al., 2009). A lack of successful, conventional 
treatment options has sparked an interest in using oncolytic viruses.  The most successful and 
popular virus being studied currently is vesicular stomatitis virus (VSV). Vesicular stomatitis 
virus is a relatively non-pathogenic, negative-stranded RNA virus that can preferentially 
replicate in malignant cells and less so in normal cells (Barber, 2004).  The virus’s short life 
cycle allows for frequent and quick replication before the host cells antibodies begin to do their 
job and destroy the virus.  Interferon alpha is a key aspect of the innate immune response and 
VSV happens to be particularly susceptible to it.  Tumor cells have a defective interferon 
pathway, which allows the virus to replicate quickly and cause necrosis.  The healthy cells are 
able to defend themselves and destroy the virus.  In this study, the combination of a recombinant 
VSV and interferon alpha are used to treat rats with HCC.  Hopefully the two used in 




Hepatocellular carcinoma (HCC) is a 
type of liver cancer common in adults that 
accounts for over one million cases annually 
(Altomonte et al., 2009). The potentially 
curative treatment options that are available 
to patients today are liver transplantation 
and surgical resection, though these 
treatments can only be applied to a small 
number of patients (Marozin et al., 2010). 
Other local treatments that can be applied to 
many patients have been shown to have 
frequent recurrence and poor long-term 
survival (Marozin et al., 2010). This lack of 
successful treatment options has sparked an 
interest in using oncolytic viruses. 
The most successful and popular 
virus being studied currently is vesicular 
stomatitis virus (VSV). VSV is a member of 
the Rhabdoviridae family, genera 
Vesiculovirus and a relative to the rabies 
virus genera Lyssavirus. The virus is bullet 
shaped in structure and encodes for only five 
proteins. Vesicular stomatitis virus is a 
relatively non-pathogenic, negative-stranded 
RNA virus that can preferentially replicate 
in malignant cells and less so in normal cells 
(Barber, 2004). The virus’s short life cycle 
allows for frequent and quick replication 
before the host cells antibodies begin to do 
their job and destroy the virus. This virus is 
usually asymptomatic in humans, while 
production animals such as cattle and swine 
can be non-lethally infected and develop 
lesions on their mucosal membranes 
(Barber, 2004). A benefit to using this 
particular virus in the treatment of cancer is 
that vesicular stomatitis virus is not endemic 
to North America, meaning there should be 
no preexisting neutralizing antibodies or 
memory cell immune responses to interfere 
with its replication potential (Altomonte et 
al., 2009). 
 
VSV AS AN ONCOLYTIC VECTOR 
 
To better understand how VSV can 
replicate in tumor cells and cause necrosis, 
the body’s innate immune response and how 
that protects the host from infection must be 
understood. The first line of defense against 
an invading pathogen is the innate immune 
response. The synthesis and secretion of 
Type 1 interferons (IFN) alpha and beta, are 
a key aspect of this response. Interferons are 
known to exert potent antitumor, anti-viral, 
and immunomodulatory activities (Barber, 
2004), which is key in protecting the host. 
Two events are required to trigger an 
effective anti-viral innate immune response: 
1) detection of the invading virus by 
immune system receptors; and 2) initiation 
of protein signaling cascades that regulate 
the synthesis of IFNs (Seth et al., 2006). 
While it is not quite clear how induction of 
the IFN-alpha promoter is regulated or 
induced, it is possibly done via three 
different pathways. What is known, 
however, is that these three pathways 
converge on TRAF3 (a protein in the 
cytoplasm), which induces interferon 
production through the activation of other 
protein complexes (Pietras et al., 2006). IFN 
alpha and beta are synthesized by most cell 
types and share a common receptor 
(Balachandran et al., 2000), so they are 
readily available in the body. 
Once IFN alpha/beta is produced, it 
induces the production of protein kinase 
RNA-activated (PKR), which is a 
component of the host’s defense 
mechanisms, designed to restrict viral 
replication. The function of PKR is to inhibit 
virus translation to buy time for other 
members of the innate immune response, 
such as neutralizing antibodies, to be 
produced and strengthen the antiviral state. 
It buys time by interacting with a double-
stranded RNA (dsRNA), which causes PKR 
to autophosphorylate and to catalyze the 
phosphorylation of substrate targets 
(Balachandran et al., 2000). The best 
example being a reduction in protein 
synthesis rates in the cell. With a reduced 
amount of protein being made, the cell 
cannot function at a normal level and will 
affect any body system that needs that 
protein to function. 
Another way the alpha and beta 
interferons aid the immune response is 
through virus-induced apoptosis of cells. 
Cell surface death receptors such as 
FAS/CD95, a member of the tumor necrosis 
factor receptor (TNFR) family, are ligated. 
This ligation leads to the recruitment and 
activation of the adaptor protein, FADD, and 
caspases, a family of cystein proteases that 
exist as inactive zymogens (any of a group 
of compounds that are inactive precursors of 
enzymes and are activated by a kinase) in 
normal cells (Balachandran et al., 2000). 
The cleavage of caspases, ultimately 
caspase-3, leads to the beginnings of 
apoptosis. 
In normal cells, VSV is sensitive to 
the antiviral actions of alpha/beta interferons 
and the virus is destroyed. In many types of 
tumors these pathways are defective, 
allowing the virus to replicate. Replication 
of the virus occurs in the cyptoplasm of 
infected cells, which occurs independently 
of the cell cycle, and it preferentially kills 
cells that undergo mitosis (Marozin et al., 
2010). In a normal cell, it is possible that 
IFN prevents apoptosis by blocking the early 
replication stages. 
To determine whether it was a 
defective pathway that allowed this virus to 
be so effective, normal cells were treated 
with IFN-alpha and exposed to VSV and 
HCC tumor cells were exposed to VSV 
(Barber, 2004). Data indicated the normal 
cells were much more protected than the 
tumor cells. In the review done by Barber 
(2004), he plausibly indicated that following 
intravenous inoculation, VSV must infect a 
number of the animal’s normal cells as well 
as the tumor cells. He stated that in this 
scenario, the IFN system would be activated 
within the normal cells and the virus 
replication thwarted. Secreted IFN from 
innocuously targeted cells, including high 
level IFN-producing plasmacytoid dendritic 
cells would activate anti-viral pathways in 
surrounding uninfected normal cells, 
causing them and the animal in general, to 
become resistant to VSV infection. In 
contrast to this, Barber (2004) stated that 
tumor cells would allow the replication of 
VSV to proceed, due to their harboring 
defects in innate immune responses, and 
would lyse. Progeny viruses would, in turn, 
infect surrounding tumor cells and the 
process would begin again. This further 
supports the claim that it is the dysfunctional 
tumor cells that allow the virus to replicate 
and cause tumor shrinkage. 
In earlier studies done by the group 
at Mt. Sinai, the wild type VSV, at levels 
similar to patient doses, induced a systemic 
proinflammatory cytokine response. This 
response might have been a contributing 
factor to lethal hepatotoxicity in the rats 
treated (Shinozaki et al., 2005). Signs of 
neurotoxicity include altered consciousness, 
excitability, and limb paralysis (Shinozaki et 
al., 2005). The wild type was also unable to 
establish an effective amount of tumor 
regression due to the host’s immune 
response destroying the virus. In order for 
the virus to be successful, the host’s immune 
response must first be suppressed. A 
recombinant version of the virus was created 
by this group that expressed equine herpes 
virus-1 glycoprotein G (rVSV-gG). This 
broad-spectrum viral chemokin binding 
protein was able to suppress the body’s 
immune response. Although regression of 
the lesions in the liver were observed, 
complete tumor regression and long-term 
survival were not observed in the treated 
animals and they eventually relapsed (Wu et 
al., 2008). In the most recent study this 
group created another recombinant version 
of the virus that expressed M3, a chemokin-
binding protein from murine 
gammaherpesvirus-68 (rVSV(MΔ51)-M3). 
Another benefit to this strain is the mutation 
in its matrix (M) at position 51, which 
results in an IFN-inducing phenotype (Wu et 
al., 2008). In this study, treated rats had a 
prolonged life with a 50% survival rate. 
Now they are looking at adding IFN-alpha 
to the treatment plan to better protect the 
normal cells and leave the tumor cells more 
susceptible to the virus. Hopefully, these 
two treatments working in conjunction can 
have a better, more positive result in the 
amount of tumor regression and prolonged 
survival rate in the rats and can advance to 
use in human medicine. 
 
MATERIALS AND METHODS 
 
 The animal protocol for the hepatic 
artery injection is done by Marcia Meseck 
and follows the procedures as designated in 
the Handbook of Laboratory Animal 
Medicine. All sterile cotton swabs, gauze, 
and sponges are soaked in sterile phosphate 
buffered saline (PBS) solution. The rats are 
anesthetized using a VetEquip Isoflurane 
anesthesia chamber with the isoflurane level 
at 3 and oxygen level set at 2. The entire 
procedure is done in the biological safety 
cabinet and the rats are placed on sterile 
absorbent pads with their nose placed in the 
cone of the anesthesia machine. The hair is 
shaved on the abdomen and the skin is 
disinfected with 70% ethanol. A midline 
laparotomy (~3 cm long) is made and the 
left and right lobes of the liver and the 
intestines are gently moved to the exterior of 
the animal using a sterile, moistened cotton 
swab. The organs are covered with 
moistened gauze to prevent them from 
drying out. The membranes covering the 
liver lobes are cut to expose the common 
hepatic artery. The hepatic vessels (common 
hepatic artery, proper hepatic artery, and 
gastroduodenal artery) are gently exposed 
using a forceps and scissors without cutting 
any vessels or tissues. The gastroduodenal 
artery is ligated and the common hepatic 
artery was temporarily blocked using a 
micro clamp. The appropriate volume of the 
virus was slowly administered into the 
gatroduodenal artery. After the entire 
volume is administered, the proximal side of 
the gastroduodenal artery is ligated to 
prevent bleeding, the micro clamp is 
removed from the common hepatic artery, 
and the presence of appropriate hepatic 
blood flow is confirmed. The intestines and 
liver lobes are returned to their physiological 
position. The abdominal incision is closed 
with sutures and the rat is placed back in its 
cage on its stomach. Each rat is also 
administered buprenorphine (analgesic) 
subcutaneously and ear tagged with the 
appropriate number. 
 
Figure 1. Hepatic Arterial Infusion of VSV in Multi-







Figure 2. Multifocal HCC-bearing rats were injected 
with three different virus strains at different dosages. 
Rats were killed 3 days after virus adminstration. 
Viral titers show the virus most effective at staying in 




Figure 3. Tumor necrosis in rats treated with the 
same three strains of VSV. The percentage was the 
highest in the rVSV(MΔ51)-M3 strain and was 
determined by statistical analysis (Wu et al., 2008). 
 
Figure 4. The box represent the rVSV(MΔ51)-M3 
strain of the virus at the same three dosages and the 
other group of lines represent the other two strains 
used at the same dosages. Survival of the rats was 
observed daily and the highest survival percentage 





Since the pathology results from this 
study will not be received for a couple of 
months, data was taken from the previous 
study with the recombinant virus 
rVSV(MΔ51)-M3 and speculations were 
made from these results with the addition of 
IFN-alpha.  The results with the addition of 
IFN-alpha, should have an increased level of 
titers, necrosis, and survival since IFN-alpha 
should increase protection of the healthy 
cells, while leaving the tumor cells more 
susceptible to VSV. Hopefully, when the 





The main limitation of this study is 
the host’s immune response. Every 
individual could respond to the introduction 
of VSV differently, despite the results 
concluded in the study. If an individual’s 
innate immune system were particularly 
strong, this course of treatment for 
hepatocellular carcinoma would be 
ineffective. The probability of this occurring 
is difficult to predict and would most likely 
not occur, but nonetheless, it is always a 
possibility. The other extreme would be the 
patient’s immune system is not strong 
enough to fight off the virus. In this case not 
only tumor cells would be targeted, but 
normal, healthy cells could be affected as 
well. Patient death may even result, as the 
recombinant version of the virus is able to 
suppress the immune system in order to do 
its job. An opportunistic infection that 
normally could be defended against, in the 
immune suppressed state of the host, could 
be harmful. Another limitation in the actual 
study is the time it takes to get the pathology 
results back. Speculations to whether or not 
the treatment was effective can be made, 
however, actual data to confirm those results 




The success of vesicular stomatitis 
virus as an oncolytic agent has prompted 
several other RNA viruses to be looked at 
for their oncolytic properties and some are 
even being used in clinical trials. Some of 
these viruses include reovirus, Newcastle 
disease virus, measles virus, vaccinia virus, 
and the influenza virus (Ausubel et al., 
2011). Oncolytic viruses are now being 
looked at as treatment options for different 
cancers such as brain cancer and work has 
already begun to find a virus successful in 
the treatment of breast cancer. Many of 
these viruses that cause cancers, for example 
Hepatitis C is involved with Hepatocellular 
Carcinoma, have devised strategies to 
subdue the IFN/innate immune pathway to 
avoid destruction, so these cancers should be 
extremely susceptible to VSV 
(Balachandran et al., 2000; Barber, 2004). 
The idea that a virus, something our body 
naturally protects us against, can be 
beneficial to us is something that seems hard 
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